Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017

This report provides an overview of the pipeline landscape for neuropsychiatric disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), Depression, Schizophrenia, and Tourette syndrome, and features dormant and discontinued projects.

Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness, with symptoms including disorganized work habits, procrastination and inability to sustain attention on tasks or activities.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches.

Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior.

Finally, Tourette syndrome is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking.

The size of these pipelines ranges from 11 products in Tourette syndrome to 191 in depression. Across all four of these indications, however, transporters and receptors of neurotransmitters such as dopamine and serotonin are the most common targets, closely reflecting the current treatment landscape of these diseases.

Scope

– Which companies are the most active within the pipeline for genetic neuropsychiatric disorder therapeutics?

– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

– What are the most important R&D milestones and data publications to have happened in the field of genetic neuropsychiatric disorders?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

Table of Contents

GBI Research Report Guidance 2

Executive Summary 3

Table of Contents 4

List of Tables 6

List of Figures 12

Introduction 13

Neuropsychiatric Disorder Cluster Report Coverage 13

Attention Deficit Hyperactivity Disorder (ADHD) - Overview 13

Depression - Overview 13

Schizophrenia - Overview 13

Tourette Syndrome - Overview 13

Therapeutics Development 14

Attention Deficit Hyperactivity Disorder (ADHD) 14

Depression 22

Schizophrenia 36

Tourette Syndrome 47

Therapeutics Assessment 50

Attention Deficit Hyperactivity Disorder (ADHD) 50

Depression 57

Schizophrenia 68

Tourette Syndrome 78

Companies Involved in Therapeutics Development 84

Attention Deficit Hyperactivity Disorder (ADHD) 84

Depression 101

Schizophrenia 148

Tourette Syndrome 185

Dormant Projects 189

Attention Deficit Hyperactivity Disorder (ADHD) 189

Depression 192

Schizophrenia 201

Tourette Syndrome 206

Discontinued Products 207

Attention Deficit Hyperactivity Disorder (ADHD) 207

Depression 208

Schizophrenia 211

Tourette Syndrome 212

Product Development Milestones 213

Attention Deficit Hyperactivity Disorder (ADHD) 213

Depression 224

Schizophrenia 233

Tourette Syndrome 243

Appendix 253

Methodology 253

Coverage 253

Secondary Research 253

Primary Research 253

Expert Panel Validation 253

Contact Us 253

Disclaimer 254

List of Tables

List of Tables

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD) 14

Number of Products under Development by Companies, Attention Deficit Hyperactivity Disorder (ADHD) 16

Number of Products under Development by Universities/Institutes, Attention Deficit Hyperactivity Disorder (ADHD) 17

Products under Development by Companies, Attention Deficit Hyperactivity Disorder (ADHD) 18

Products under Development by Universities/Institutes, Attention Deficit Hyperactivity Disorder (ADHD) 21

Number of Products under Development for Depression 22

Number of Products under Development by Companies, Depression 24

Number of Products under Development by Universities/Institutes, Depression 27

Products under Development by Companies, Depression 28

Products under Development by Universities/Institutes, Depression 34

Number of Products under Development for Schizophrenia 36

Number of Products under Development by Companies, Schizophrenia 38

Number of Products under Development by Universities/Institutes, Schizophrenia 40

Products under Development by Companies, Schizophrenia 41

Products under Development by Universities/Institutes, Schizophrenia 46

Number of Products under Development for Tourette Syndrome 47

Number of Products under Development by Companies, Tourette Syndrome 48

Number of Products under Development by Universities/Institutes, Tourette Syndrome 49

Products under Development by Companies, Tourette Syndrome 49

Products under Development by Universities/Institutes, Tourette Syndrome 49

Number of Products by Stage and Target, Attention Deficit Hyperactivity Disorder (ADHD) 51

Number of Products by Stage and Mechanism of Action, Attention Deficit Hyperactivity Disorder (ADHD) 53

Number of Products by Stage and Route of Administration, Attention Deficit Hyperactivity Disorder (ADHD) 55

Number of Products by Stage and Molecule Type, Attention Deficit Hyperactivity Disorder (ADHD) 56

Number of Products by Stage and Target, Depression 58

Number of Products by Stage and Mechanism of Action, Depression 62

Number of Products by Stage and Route of Administration, Depression 66

Number of Products by Stage and Molecule Type, Depression 68

Number of Products by Stage and Target, Schizophrenia 70

Number of Products by Stage and Mechanism of Action, Schizophrenia 73

Number of Products by Stage and Route of Administration, Schizophrenia 76

Number of Products by Stage and Molecule Type, Schizophrenia 78

Number of Products by Stage and Target, Tourette Syndrome 79

Number of Products by Stage and Mechanism of Action, Tourette Syndrome 81

Number of Products by Stage and Route of Administration, Tourette Syndrome 83

Number of Products by Stage and Molecule Type, Tourette Syndrome 83

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Aevi Genomic Medicine Inc 84

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Alcobra Ltd 84

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Amarantus Bioscience Holdings Inc 85

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by APeT Holding BV 85

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Arbor Pharmaceuticals LLC 86

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by BCWorld Pharm Co Ltd 86

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by BioHealthonomics Inc 87

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by BioLite Inc 87

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Cingulate Therapeutics LLC 88

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Collegium Pharmaceutical Inc 88

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Curemark LLC 89

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by DURECT Corp 89

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Eli Lilly and Company 90

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Ensysce Biosciences Inc 90

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by H. Lundbeck A/S 91

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Heptares Therapeutics Ltd 91

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Highland Therapeutics Inc 92

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Integrative Research Laboratories Sweden AB 92

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by INVENT Pharmaceuticals Inc 93

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by KemPharm Inc 93

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Luc Therapeutics Inc 94

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Merck & Co Inc 94

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Neos Therapeutics Inc 95

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by NeuroDerm Ltd 95

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Neurovance Inc 96

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by NLS Pharma Group 96

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Noven Pharmaceuticals Inc 97

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by P2D Bioscience 97

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Reviva Pharmaceuticals Inc 98

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Shire Plc 98

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by SK Biopharmaceuticals Co Ltd 99

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Sunovion Pharmaceuticals Inc 99

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Supernus Pharmaceuticals Inc 100

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Taisho Pharmaceutical Co Ltd 100

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by TRImaran Pharma Inc 101

Depression – Pipeline by 4D Pharma PLC 101

Depression – Pipeline by AB Science SA 102

Depression – Pipeline by Acadia Pharmaceuticals Inc 102

Depression – Pipeline by Adamed Sp z oo 103

Depression – Pipeline by Addex Therapeutics Ltd 103

Depression – Pipeline by Aequus Pharmaceuticals Inc 104

Depression – Pipeline by Alkermes Plc 104

Depression – Pipeline by Allergan Plc 105

Depression – Pipeline by Alvogen Korea Co Ltd 105

Depression – Pipeline by Amorsa Therapeutics Inc 106

Depression – Pipeline by Anavex Life Sciences Corp 106

Depression – Pipeline by Angelini Group 107

Depression – Pipeline by Angita BV 107

Depression – Pipeline by Araim Pharmaceuticals Inc 107

Depression – Pipeline by AstraZeneca Plc 108

Depression – Pipeline by Avanir Pharmaceuticals Inc 108

Depression – Pipeline by Axsome Therapeutics Inc 109

Depression – Pipeline by Azevan Pharmaceuticals Inc 109

Depression – Pipeline by BioCrea GmbH 110

Depression – Pipeline by BioLite Inc 110

Depression – Pipeline by Bionomics Ltd 111

Depression – Pipeline by Boehringer Ingelheim GmbH 111

Depression – Pipeline by Bristol-Myers Squibb Company 112

Depression – Pipeline by Calico LLC 112

Depression – Pipeline by Celgene Corp 113

Depression – Pipeline by Celon Pharma SA 113

Depression – Pipeline by Cerecor Inc 114

Depression – Pipeline by Clera Inc 114

Depression – Pipeline by Delpor Inc 115

Depression – Pipeline by Domain Therapeutics SA 115

Depression – Pipeline by Eisai Co Ltd 116

Depression – Pipeline by Eli Lilly and Company 116

Depression – Pipeline by Evotec AG 117

Depression – Pipeline by F. Hoffmann-La Roche Ltd 117

Depression – Pipeline by Fabre-Kramer Pharmaceuticals Inc 118

Depression – Pipeline by FPRT Bio Inc 118

Depression – Pipeline by GlaxoSmithKline Plc 119

Depression – Pipeline by GliaCure Inc 119

Depression – Pipeline by H. Lundbeck A/S 120

Depression – Pipeline by Heptares Therapeutics Ltd 120

Depression – Pipeline by Hua Medicine (Shanghai) Ltd 121

Depression – Pipeline by Hyundai Pharmaceutical Co Ltd 121

Depression – Pipeline by Impel NeuroPharma Inc 122

Depression – Pipeline by INSYS Therapeutics Inc 122

Depression – Pipeline by Intas Pharmaceuticals Ltd 123

Depression – Pipeline by Intra-Cellular Therapies Inc 123

Depression – Pipeline by INVENT Pharmaceuticals Inc 124

Depression – Pipeline by Johnson & Johnson 124

Depression – Pipeline by KemPharm Inc 125

Depression – Pipeline by Lead Discovery Center GmbH 125

Depression – Pipeline by Les Laboratoires Servier SAS 126

Depression – Pipeline by Lixte Biotechnology Holdings Inc 126

Depression – Pipeline by Luye Pharma Group Ltd 127

Depression – Pipeline by Mapi Pharma Ltd 127

Depression – Pipeline by Mapreg SAS 128

Depression – Pipeline by Medlab Clinical Ltd 128

Depression – Pipeline by Meta-IQ ApS 129

Depression – Pipeline by Methylation Sciences Inc 129

Depression – Pipeline by miCure Therapeutics Ltd 130

Depression – Pipeline by Mitsubishi Tanabe Pharma Corp 130

Depression – Pipeline by Navya Biologicals Pvt Ltd 131

Depression – Pipeline by Neuralstem Inc 131

Depression – Pipeline by Neurocrine Biosciences Inc 132

Depression – Pipeline by NeuroNascent Inc 132

Depression – Pipeline by NeurOp Inc 133

Depression – Pipeline by Newron Pharmaceuticals SpA 133

Depression – Pipeline by Nippon Chemiphar Co Ltd 134

Depression – Pipeline by nLife Therapeutics SL 134

Depression – Pipeline by Omeros Corp 135

Depression – Pipeline by Orexigen Therapeutics Inc 135

Depression – Pipeline by Otsuka Holdings Co Ltd 136

Depression – Pipeline by Pfizer Inc 137

Depression – Pipeline by Pherin Pharmaceuticals Inc 137

Depression – Pipeline by Polleo Pharma Ltd 138

Depression – Pipeline by Protagenic Therapeutics Inc 138

Depression – Pipeline by Relmada Therapeutics Inc 139

Depression – Pipeline by Reviva Pharmaceuticals Inc 139

Depression – Pipeline by Richter Gedeon Nyrt 140

Depression – Pipeline by Sage Therapeutics Inc 140

Depression – Pipeline by Saniona AB 141

Depression – Pipeline by SK Biopharmaceuticals Co Ltd 141

Depression – Pipeline by Sound Pharmaceuticals Inc 142

Depression – Pipeline by Sumitomo Dainippon Pharma Co Ltd 142

Depression – Pipeline by Supernus Pharmaceuticals Inc 143

Depression – Pipeline by Suven Life Sciences Ltd 143

Depression – Pipeline by Taisho Pharmaceutical Holdings Co Ltd 144

Depression – Pipeline by Takeda Pharmaceutical Company Ltd 144

Depression – Pipeline by Tetra Discovery Partners LLC 145

Depression – Pipeline by Trevena Inc 145

Depression – Pipeline by TRImaran Pharma Inc 146

Depression – Pipeline by VistaGen Therapeutics Inc 146

Depression – Pipeline by Zhejiang Huahai Pharmaceutical Co Ltd 147

Depression – Pipeline by Zogenix Inc 147

Depression – Pipeline by Zysis Ltd 148

Schizophrenia – Pipeline by Acadia Pharmaceuticals Inc 148

Schizophrenia – Pipeline by Adamed Sp z oo 149

Schizophrenia – Pipeline by Aequus Pharmaceuticals Inc 149

Schizophrenia – Pipeline by AgeneBio Inc 150

Schizophrenia – Pipeline by Alkermes Plc 150

Schizophrenia – Pipeline by Angita BV 151

Schizophrenia – Pipeline by Astellas Pharma Inc 151

Schizophrenia – Pipeline by Athersys Inc 152

Schizophrenia – Pipeline by Avanir Pharmaceuticals Inc 152

Schizophrenia – Pipeline by Avineuro Pharmaceuticals Inc 153

Schizophrenia – Pipeline by BCWorld Pharm Co Ltd 153

Schizophrenia – Pipeline by BioCrea GmbH 154

Schizophrenia – Pipeline by BioHealthonomics Inc 154

Schizophrenia – Pipeline by Boehringer Ingelheim GmbH 154

Schizophrenia – Pipeline by Braeburn Pharmaceuticals Inc 155

Schizophrenia – Pipeline by Bristol-Myers Squibb Company 155

Schizophrenia – Pipeline by Critical Pharmaceuticals Ltd 156

Schizophrenia – Pipeline by Curemark LLC 156

Schizophrenia – Pipeline by Daewoong Pharmaceutical Co Ltd 157

Schizophrenia – Pipeline by Delpor Inc 157

Schizophrenia – Pipeline by Denovo Biopharma LLC 158

Schizophrenia – Pipeline by Evotec AG 158

Schizophrenia – Pipeline by F. Hoffmann-La Roche Ltd 159

Schizophrenia – Pipeline by Fabre-Kramer Pharmaceuticals Inc 159

Schizophrenia – Pipeline by Galenea Corp 160

Schizophrenia – Pipeline by GeNeuro SA 160

Schizophrenia – Pipeline by GlaxoSmithKline Plc 161

Schizophrenia – Pipeline by Glenmark Pharmaceuticals Ltd 161

Schizophrenia – Pipeline by GP Pharm SA 162

Schizophrenia – Pipeline by GW Pharmaceuticals Plc 162

Schizophrenia – Pipeline by H. Lundbeck A/S 163

Schizophrenia – Pipeline by Heptares Therapeutics Ltd 163

Schizophrenia – Pipeline by Hisamitsu Pharmaceutical Co Inc 164

Schizophrenia – Pipeline by Indivior Plc 164

Schizophrenia – Pipeline by Insys Therapeutics Inc 165

Schizophrenia – Pipeline by IntelGenx Corp 165

Schizophrenia – Pipeline by Intra-Cellular Therapies Inc 166

Schizophrenia – Pipeline by Johnson & Johnson 166

Schizophrenia – Pipeline by JT Pharmaceuticals Inc 167

Schizophrenia – Pipeline by Karuna Pharmaceuticals Inc 167

Schizophrenia – Pipeline by KemPharm Inc 168

Schizophrenia – Pipeline by Kowa Company Ltd 168

Schizophrenia – Pipeline by Laboratorios Farmaceuticos Rovi SA 169

Schizophrenia – Pipeline by Lead Discovery Center GmbH 169

Schizophrenia – Pipeline by Lohocla Research Corp 170

Schizophrenia – Pipeline by Luye Pharma Group Ltd 170

Schizophrenia – Pipeline by Mapi Pharma Ltd 171

Schizophrenia – Pipeline by Merck & Co Inc 171

Schizophrenia – Pipeline by Mitsubishi Tanabe Pharma Corp 172

Schizophrenia – Pipeline by Neurocrine Biosciences Inc 172

Schizophrenia – Pipeline by NeurOp Inc 173

Schizophrenia – Pipeline by Newron Pharmaceuticals SpA 173

Schizophrenia – Pipeline by Omeros Corp 174

Schizophrenia – Pipeline by Otsuka Holdings Co Ltd 175

Schizophrenia – Pipeline by Peptron Inc 175

Schizophrenia – Pipeline by Pfizer Inc 176

Schizophrenia – Pipeline by Promentis Pharmaceuticals Inc 176

Schizophrenia – Pipeline by Ra Pharmaceuticals Inc 177

Schizophrenia – Pipeline by Reviva Pharmaceuticals Inc 177

Schizophrenia – Pipeline by Richter Gedeon Nyrt 178

Schizophrenia – Pipeline by Sage Therapeutics Inc 178

Schizophrenia – Pipeline by SK Biopharmaceuticals Co Ltd 179

Schizophrenia – Pipeline by Sumitomo Dainippon Pharma Co Ltd 179

Schizophrenia – Pipeline by Sunovion Pharmaceuticals Inc 180

Schizophrenia – Pipeline by Suven Life Sciences Ltd 180

Schizophrenia – Pipeline by Taisho Pharmaceutical Holdings Co Ltd 181

Schizophrenia – Pipeline by Tetra Discovery Partners LLC 181

Schizophrenia – Pipeline by Teva Pharmaceutical Industries Ltd 182

Schizophrenia – Pipeline by Vanda Pharmaceuticals Inc 182

Schizophrenia – Pipeline by Vitality Biopharma Inc 183

Schizophrenia – Pipeline by VLP Therapeutics LLC 183

Schizophrenia – Pipeline by Zogenix Inc 184

Schizophrenia – Pipeline by Zysis Ltd 184

Tourette Syndrome – Pipeline by Abide Therapeutics Inc 185

Tourette Syndrome – Pipeline by Catalyst Pharmaceuticals Inc 185

Tourette Syndrome – Pipeline by Neurocrine Biosciences Inc 186

Tourette Syndrome – Pipeline by Psyadon Pharmaceuticals Inc 186

Tourette Syndrome – Pipeline by Reviva Pharmaceuticals Inc 187

Tourette Syndrome – Pipeline by Synchroneuron Inc 187

Tourette Syndrome – Pipeline by Teva Pharmaceutical Industries Ltd 188

Tourette Syndrome – Pipeline by Therapix Biosciences Ltd 188

Attention Deficit Hyperactivity Disorder (ADHD) – Dormant Projects 189

Depression – Dormant Projects 192

Schizophrenia – Dormant Projects 201

Tourette Syndrome – Dormant Projects 206

Attention Deficit Hyperactivity Disorder (ADHD) – Discontinued Products 207

Depression – Discontinued Products 208

Schizophrenia – Discontinued Products 211

Tourette Syndrome – Discontinued Products 212

List of Figures

List of Figures

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD) 14

Number of Products under Development by Companies, Attention Deficit Hyperactivity Disorder (ADHD) 15

Number of Products under Development by Universities/Institutes, Attention Deficit Hyperactivity Disorder (ADHD) 17

Number of Products under Development for Depression 22

Number of Products under Development by Companies, Depression 23

Number of Products under Development by Universities/Institutes, Depression 27

Number of Products under Development for Schizophrenia 36

Number of Products under Development by Companies, Schizophrenia 37

Number of Products under Development by Universities/Institutes, Schizophrenia 40

Number of Products under Development for Tourette Syndrome 47

Number of Products under Development by Companies, Tourette Syndrome 48

Number of Products by Top 10 Targets, Attention Deficit Hyperactivity Disorder (ADHD) 50

Number of Products by Stage and Top 10 Targets, Attention Deficit Hyperactivity Disorder (ADHD) 50

Number of Products by Top 10 Mechanism of Actions, Attention Deficit Hyperactivity Disorder (ADHD) 52

Number of Products by Stage and Top 10 Mechanism of Actions, Attention Deficit Hyperactivity Disorder (ADHD) 52

Number of Products by Routes of Administration, Attention Deficit Hyperactivity Disorder (ADHD) 54

Number of Products by Stage and Routes of Administration, Attention Deficit Hyperactivity Disorder (ADHD) 54

Number of Products by Molecule Types, Attention Deficit Hyperactivity Disorder (ADHD) 55

Number of Products by Stage and Molecule Types, Attention Deficit Hyperactivity Disorder (ADHD) 56

Number of Products by Top 10 Targets, Depression 57

Number of Products by Stage and Top 10 Targets, Depression 57

Number of Products by Top 10 Mechanism of Actions, Depression 61

Number of Products by Stage and Top 10 Mechanism of Actions, Depression 61

Number of Products by Top 10 Routes of Administration, Depression 65

Number of Products by Stage and Top 10 Routes of Administration, Depression 65

Number of Products by Molecule Types, Depression 67

Number of Products by Stage and Molecule Types, Depression 67

Number of Products by Top 10 Targets, Schizophrenia 68

Number of Products by Stage and Top 10 Targets, Schizophrenia 69

Number of Products by Top 10 Mechanism of Actions, Schizophrenia 72

Number of Products by Stage and Top 10 Mechanism of Actions, Schizophrenia 72

Number of Products by Routes of Administration, Schizophrenia 75

Number of Products by Stage and Routes of Administration, Schizophrenia 75

Number of Products by Molecule Types, Schizophrenia 77

Number of Products by Stage and Molecule Types, Schizophrenia 77

Number of Products by Top 10 Targets, Tourette Syndrome 78

Number of Products by Stage and Top 10 Targets, Tourette Syndrome 79

Number of Products by Top 10 Mechanism of Actions, Tourette Syndrome 80

Number of Products by Stage and Top 10 Mechanism of Actions, Tourette Syndrome 80

Number of Products by Top 10 Routes of Administration, Tourette Syndrome 82

Number of Products by Stage and Routes of Administration, Tourette Syndrome 82

Number of Products by Stage and Molecule Types, Tourette Syndrome 83

    Pricing

Quick Buy
Add to basket Request sample pages

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports